Calendar

Week of Apr 20, 2026

Apr 24, 2026phase 1 initiation110d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

full page →CMSD-001 →source: globaldata

Apr 24, 2026phase 2 completion110d agoKothiwal Dental College and Research Centre — platelet rich plasma (Phase II Trial Completion)platelet rich plasma

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →platelet rich plasma →source: globaldata

Apr 24, 2026phase 2 initiation110d agoSRM Kattankulathur Dental College and Hospital — human placental extract (Phase II Trial Initiation)human placental extract

Therapy area: Dermatology. Indication: Wounds

full page →human placental extract →source: globaldata

Apr 24, 2026phase 3 completion110d agoBioClever 2005 SL — minoxidil (Phase III Trial Completion)minoxidil

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →minoxidil →source: globaldata

Apr 24, 2026phase iv trial initiation110d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

full page →carboxymethylcellulose →source: globaldata

Apr 25, 2026phase 0 trial completion109d agoExegenesis Bio Inc — EXG-202 (Phase 0 Trial Completion)EXG-202

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Macular Degeneration, Wet (Neovascular / Exudative) Macular Degeneration

full page →EXG-202 →source: globaldata

Apr 25, 2026phase 2 initiation109d agoGlenmark Pharmaceuticals Ltd — (clascoterone + latanoprost) (Phase II Trial Initiation)(clascoterone + latanoprost)

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →(clascoterone + latanoprost) →source: globaldata

Apr 26, 2026constraining patent expiry europe108d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Europe))BB-101

Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

full page →BB-101 →source: globaldata

Apr 26, 2026patent expiry108d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

full page →BB-101 →source: globaldata

Apr 26, 2026phase 2 completion108d agoCentral Council for Research in Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

Therapy area: Ophthalmology. Indication: Asthenopia (Eye Strain), Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

full page →unani medicine →source: globaldata

Apr 26, 2026phase 2 completion108d agoChongqing Jinsaixing Medical Technology Co Ltd — Neauvia Intense (Phase II Trial Completion)Neauvia Intense

Therapy area: Dermatology. Indication: Wrinkles

full page →Neauvia Intense →source: globaldata

Apr 26, 2026phase 2 initiation108d agoBeijing Chao-Yang Hospital — oxymetazoline hydrochloride (Phase II Trial Initiation)oxymetazoline hydrochloride

Therapy area: Ophthalmology. Indication: Blepharitis, Ptosis

full page →oxymetazoline hydrochloride →source: globaldata

Apr 26, 2026phase 2 initiation108d agoChittagong Medical College — difelikefalin (Phase II Trial Initiation)difelikefalin

Therapy area: Dermatology, Genito Urinary System. Indication: Chronic Kidney Disease (Chronic Renal Failure), Pruritus

full page →difelikefalin →source: globaldata

Apr 26, 2026phase iii iv trial completion108d agoRajaRajeswari Medical College & Hospital — stromal vascular fraction (Phase III/IV Trial Completion)stromal vascular fraction

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →stromal vascular fraction →source: globaldata

Week of Apr 27, 2026

Apr 27, 2026pdufa107d agoRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)dupilumab

Therapy area: Dermatology. Indication: Chronic Urticaria

full page →dupilumab →source: globaldata

Apr 27, 2026phase 1 initiation

Week of Apr 20, 2026

Week of Apr 27, 2026